California Public Employees Retirement System increased its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 1.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 116,200 shares of the biotechnology company’s stock after purchasing an additional 1,681 shares during the period. California Public Employees Retirement System’s holdings in Atara Biotherapeutics were worth $1,693,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Atara Biotherapeutics by 66.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,485 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,786 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Atara Biotherapeutics by 35.8% during the 1st quarter. SG Americas Securities LLC now owns 10,828 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 2,855 shares in the last quarter. Arizona State Retirement System bought a new stake in Atara Biotherapeutics during the 1st quarter valued at about $97,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Atara Biotherapeutics during the 1st quarter valued at about $97,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in Atara Biotherapeutics by 22.1% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,337 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 2,235 shares in the last quarter.

ATRA has been the subject of several recent research reports. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 11th. Stifel Nicolaus reduced their price target on shares of Atara Biotherapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Canaccord Genuity boosted their price target on shares of Atara Biotherapeutics from $70.00 to $78.00 and gave the company a “buy” rating in a report on Monday. Evercore ISI initiated coverage on shares of Atara Biotherapeutics in a report on Tuesday, June 30th. They issued an “outperform” rating for the company. Finally, BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $29.00.

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 4,807 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $12.09, for a total transaction of $58,116.63. Following the sale, the chief executive officer now owns 260,037 shares of the company’s stock, valued at approximately $3,143,847.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 20,116 shares of company stock worth $253,274. 4.30% of the stock is owned by insiders.

NASDAQ ATRA opened at $15.69 on Thursday. The firm has a market cap of $1.17 billion, a PE ratio of -3.13 and a beta of 2.12. The company has a 50 day moving average price of $13.09 and a 200 day moving average price of $11.38. Atara Biotherapeutics Inc has a 52 week low of $4.52 and a 52 week high of $19.36.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Wednesday, August 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.21) by $0.07. Analysts anticipate that Atara Biotherapeutics Inc will post -4.51 EPS for the current year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: Why are trading ranges significant?

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.